Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.

Antibodies show promise as candidates for therapeutics as well as tools for advancing mechanistic studies of the HER family receptors.

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and ...

A new study aimed to examine associations between dietary patterns and survival among Black women diagnosed with epithelial ...

Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and ...

Dangerous” NHS guidelines should be changed so younger men with a family history of prostate cancer like Sir Chris Hoy can be ...

Beyond that, neoantigens are not the only type of antigens available for immunotherapeutic targeting. Cancer cells also erroneously express as proteins bits of ordinarily noncoding DNA ...

Beyond that, neoantigens are not the only type of antigens available for immunotherapeutic targeting. Cancer cells also erroneously express as proteins bits of ordinarily noncoding DNA ...

A new study published in the Journal of American Medical Association showed that the combination of testing for H pylori ...

Behind breast cancer, prostate cancer is the second most common cancer in the United States. Since its opening in 2012, the ...